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Neurodevelopmental abnormalities are common in children with congenital heart disease 
and are the highest priority concern for parents and professionals following cardiac surgery 
in childhood. There is no additional routine monitoring of development for children with 
congenital heart disease in the United Kingdom hence neurodevelopmental concerns may 
be detected late, precluding early referral and intervention. 
 
Methods  
An early recognition tool (the ‘Brief Developmental Assessment’) was developed using 
quality improvement methodology involving several iterations and rounds of pilot testing. 
The requirements were for a tool covering important developmental domains and 
practicable for use within inpatient and outpatient settings by pediatric cardiac health 
professionals who are non-developmental specialists, without specialised equipment and 
which involved direct observation as well as parental report.  
 
Results  
Items were included in the tool based on existing developmental measures, covering the 
domains of gross and fine motor skills, daily living skills, communication, socialisation and 
general understanding. Items were developed for 5 age bands (0-16 weeks, 17-34 weeks, 
35-60 weeks, 15 months-2.9 years, 3-4.9 years) and the final versions included a traffic light 
scoring system for identifying children with possible delay in any or all domains. Preliminary 
testing indicated excellent inter-rater reliability, an ability to detect children with a diagnosis 
known to be associated with developmental delay, and largely acceptable internal 
reliability. 
 
Conclusion   
We report the evolution and preliminary testing of an early recognition tool for assessing 
development of children with heart disease; this was encouraging and sufficiently good to 









Neurodevelopmental problems and congenital heart disease 
Congenital heart disease (CHD) is the most common major birth defect, affecting 6-8/1000 
live births1. Improvements in medical and surgical management have resulted in a growing 
population of children and adults living with CHD and its consequences (including those 
resulting from cardiac surgery); paradoxically, improved survival, particularly of those with 
more complex CHD, translates into a greater number of children and young people living with 
significant neurodevelopmental morbidity2-4.  
Neurodevelopmental abnormalities are the most frequent morbidity in survivors of cardiac 
surgery5 and include motor deficits6-9, seizures10-13, poor executive functioning14, 
communication problems8, 15, 16, impairments in visual construction and perception15-19, poor 
attention20, 21 and learning difficulties8, 9, 21.  Deficits can range in severity and may be subtle 
and therefore more easily overlooked, particularly in children with less complex CHD, and 
throughout the course of childhood and adolescence the presentation of 
neurodevelopmental abnormalities can change.  Some deficits may resolve spontaneously, 
others may not be apparent until later childhood.  Recent longitudinal evaluation of a cohort 
of preschool-aged children at high risk of developmental delay indicated an improving 
developmental trajectory in some but approximately 20% had scores in one or more 
developmental domains which decreased over time22.  Presentation of deficits can be 
obscured or confounded by a range of factors, including those related to cardiac surgery, the 
effects of hospitalisation and other co-morbidities.  The American Heart Association23 
recently published guidelines for systematic surveillance, screening, evaluation and 
intervention to identify neurodevelopmental problems early and optimise outcomes in the 
short and longer term, building on earlier guidelines from the American Academy of 
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Pediatrics24. They also highlighted the importance of continued monitoring because the level 
of risk for neurodevelopmental impairment can change over time as different impairments 
become apparent during different periods of development.  Furthermore, children at risk for 
poor late outcomes are frequently not identified from results of early testing25.  It is therefore 
not surprising that increasing numbers of follow-up programmes for children with CHD and 
neurodevelopmental concerns are now being implemented, particularly in the United States26 
and some countries in Europe. 
 
The United Kingdom National Health Service context  
In contrast to the United States, other countries in Europe and Australia, there have been few 
published manuscripts from the United Kingdom about neurodevelopmental outcomes in 
children with CHD. However, the United Kingdom does require all pediatric cardiac centres to 
submit surgical and outcomes data to a national audit data base.  
 
During the conduct of a multi-centre study incorporating the prospective standardised 
detection of peri-operative complications and follow up of children for six months following 
pediatric cardiac surgery,27-29 it has been noted based on feedback from health professionals 
and parents that there is considerable variability in terms of follow up of developmental delay 
for children with CHD. After an acute neurological event post-surgery a child will be assessed 
by a neurologist but a child who has developmental delay in the absence of an acute 
neurological event may not be referred to a developmental specialist. Although all children 
with CHD are under follow-up with a pediatric cardiologist, such professionals are in general 
not trained to undertake developmental assessments. Children with CHD and other 
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comorbidities including developmental delay may be under the care of a pediatrician at their 
local hospital and may be referred by the cardiac centre or their pediatrician to local services 
based on suspicion of developmental delay, but there is seldom the opportunity or resources 
for any developmental testing to provide evidence to support those concerns.    
 
Every child in the United Kingdom, irrespective of any known health problems, has an 
allocated health visitor (a community based nurse or midwife) who should make a minimum 
of five key visits to every family from the antenatal period until the child is 2-2.5 years old.  
Neuro-developmental problems in children with CHD may arise from multiple aetiologies and 
at all stages in their early lives and care pathways5, 6, 10, 13 hence these may be an issue prior 
to the age of 2-2.5 years, thereby delaying recognition and intervention.  
 
A formal standardised assessment of development using comprehensive tests such as the 
Bayley Scales of Infant Development30, Griffiths Mental Development scales31 or the Mullen 
Scales of Early Learning32 is considered to be the gold standard but these are not tests that 
are used for early recognition of developmental delay. If a problem is identified and a child is 
referred for follow-up, such tests are usually undertaken by someone who has had specialist 
developmental training and has time dedicated to perform the testing.  However, if a child is 
not referred such tests are unlikely to be performed as they are not integrated into the 
routine follow-up of children.  Moreover this would not be feasible because the tests are time 
consuming and not practicable with sick children or within the context of a busy ward or 
outpatients. Of note, children may require multiple cardiac interventions and the level of risk 
may change over time, thereby necessitating some mechanism for repeated routine 
monitoring and early recognition of developmental problems in all children with CHD (a not 
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inconsiderable number). Given this whole picture, and as we know anecdotally from our own 
clinical practice, developmental delay is often detected late – frequently not until a child starts 
school and education services become involved – thereby precluding the opportunity for early 




With the above in mind, we determined that an early recognition tool would help to address 
some of the current shortcomings and facilitate appropriate and timely referral for further, 
more comprehensive neuropsychological evaluation for those in whom this is indicated.   Our 
aim was to identify an existing tool that would be fit for purpose or, failing that, to develop a 
new tool that could subsequently be validated but that would, importantly, have the potential 




Preliminary work: review of existing tools 
A multidisciplinary team of 10 experts, comprising a paediatric neurologist, developmental 
experts, paediatricians, psychologists, nurses and a statistical expert (the BDA Development 
Group) was convened. The BDA Development Group generated a set of consensus-based 
criteria for the optimal early recognition tool (Table 1) in children with heart disease. 
 
A review of the published literature was undertaken relating to children with CHD and critical 
illness in order to identify the range of neurodevelopmental assessment tools available. Tests 
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of specific domains of function [e.g. the Peabody Developmental Motor Scales33] were not 
included knowing that they do not assess all the relevant domains of neuropsychological 
functioning. The neurodevelopmental assessment tools available were evaluated against the 
stated pre-set criteria.  
 
 
Development of the Brief Developmental Assessment  
At all stages, the BDA Development Group held underpinning goals that the final version of 
the Brief Developmental Assessment should be valid, reliable, understood by, and useful to, 
health professionals, acceptable to parents, accessible, resource efficient, cover the relevant 
areas of child development for the population of CHD and aid early referral of 
neurodevelopmental problems34. 
 
Recruitment and process for developing and testing the Brief Developmental Assessment 
Stage One 
The BDA Development Group decided, by consensus and based on the age distribution of 
children undergoing paediatric cardiac surgery in the United Kingdom, on the most 
appropriate age groups. Having reviewed relevant literature on neurodevelopment in 
children with CHD and existing measures of development (see Supplementary Table 1 for 
references), the conceptual basis and content of the Brief Developmental Assessment were 
determined in terms of the domains to be assessed and individual items to be included within 
each domain. On completion of the initial questionnaire development (version one), a 
convenience sample of 50 children with a range of cardiac diagnoses and their parents were 
recruited from the cardiac inpatient or day-case ward at our Institution to assess feasibility 
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and acceptability.   Our approach to recruitment of the convenience samples reported in this 
study was that when a member of the research team was available, he/she approached all of 
the children with heart disease who were admitted to the cardiac inpatient or day-case ward 
within the specified age range who were available based on occurrence of clinical care 
procedures and those families who consented to participate then did so.  Each convenience 
sample included children considered to be at high risk for developmental disorders23 but it 
was also important that children not typically considered to be at high risk were included 
because of our aim of developing a tool which could be used with children with any cardiac 
diagnosis. Medical and nursing staff trained in the use of the Brief Developmental Assessment 
administered it to at least 5 children in each age group and parents and clinicians were asked 
to provide verbal feedback about the process of administering the Brief Developmental 
Assessment and the content of the questions, which was documented in the form of 
contemporaneous notes. The BDA Development Group then made any necessary changes to 
the content, based on the feedback, and a scoring system was added (version two).   
 
Stage Two 
A further convenience sample of 138 children (which included some children with a 
condition known to be associated with developmental delay) were recruited from the 
cardiac inpatient or day-case ward for pilot testing of version two and the Brief 
Developmental Assessment was administered by nursing or medical staff.  A preliminary 
assessment of internal reliability was undertaken by calculating Cronbach’s alpha values. For 
each age band we examined reliability across all individual scale items, between domain 
totals and within each domain.  Construct validity was assessed by comparing scores of 17 
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children in a known group with an age-matched group of 17 children who were not in a 
known group.  A Wilcoxon test for paired data was used to compare the two groups. 
Medical and nursing staff were again asked to provide verbal feedback about the content 
and scoring and members of the BDA Development Group met with a group of community 
paediatricians to receive further feedback about the presentation, scoring and utility of the 
Brief Developmental Assessment, with contemporaneous notes being taken at each 
occasion.  Further revisions were made to both the content and scoring system by the BDA 
Development Group, with some problem items adjusted, resulting in version three. 
 
Stage Three 
A ‘traffic light’ scoring system was developed by the BDA Development Group, based on 
age-appropriate norms35 36, and a detailed training guide was developed.  Inter-rater 
reliability of version three was assessed with a convenience sample of 74 children by two 
research assistants, one of whom administered the Brief Developmental Assessment and 
scored it and a second research assistant observed and independently scored the Brief 
Developmental Assessment based on the performance of the child and from the 
information provided by the parent.  The Brief Developmental Assessment scores obtained 
by the two research assistants were statistically compared using a weighted kappa for the 
gross motor score (possible range was 0-4) and an intra-class correlation-for the cognitive 
score (possible range was 0-20).  In addition, a sample of 15 parents and 7 clinicians who 
had used the Brief Developmental Assessment were informally interviewed about their 
experience of using it, in terms of ease of use and understanding, relevance, time taken and 
suitability of using it in the ward or clinic situation34, 37 and responses documented and 
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reviewed by the BDA Development Group in order to qualitatively evaluate the acceptability 
and feasibility of the Brief Developmental Assessment.   
 
The first three stages of development and preliminary testing of the Brief Developmental 
Assessment are summarised in Figure 1. In Stage 4 (January 2014), the BDA Development 
Group signed-off the final versions of the Brief Developmental Assessment in preparation for 
a more extensive validation study.  
 
Results 
The review of existing measures indicated that no single existing developmental tool fulfilled 
all of our criteria (Supplementary material – Table 1).  Several measures only failed to meet 
the criterion of having elements of both observational and parent report.   We considered 
the option of adapting one of these measures but this would have necessitated both 
reducing the parental component and adding in observational items for each domain. 
 
Content and structure 
 The age bands were age band one: 0-16 weeks, age band two: 17-34 weeks, age band 
three: 35-60 weeks, age band four: 15 months-2.9 years and age band five: 3.0-4.9 years.  
This age banding was decided by consensus between members of the BDA Development 
Group, taking into account a focus on pre-school children to facilitate early recognition of 
problems, the need for the age groups to adequately capture the natural trajectory of 
child development which is particularly rapid in the youngest children and the likely 
population of children with CHD who undergo cardiac surgery, which incorporates a large 
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proportion of very young children38.  As a result, age bands were skewed towards the 
youngest age groups. 
 The domains identified as being important from the review of the literature and existing 
developmental measures (Supplementary Table 1) determined the conceptual basis of 
the tool.  The domains were: gross motor, daily living skills, communication and 
socialisation for all ages, fine motor (from 35 weeks) and general understanding (for 
children of 17 weeks–4.9 years). Included items for each of these domains were based on 
existing measures of development30, 31 and were selected to reflect developmental 
progression within an individual age band. Behaviour items were included for children 
aged 15 months to 5 years but were not included in the scoring.  
Changes to the content and structure from version 1 to version 3 are shown in Figure 2. 
 
Scoring 
 Each individual domain in all age bands had a potential score between 0 and 4. Hence the 
Brief Developmental Assessment gross motor domain had a maximum score of 4 for all 
ages.  The remaining Brief Developmental Assessment domains corresponding closely to 
cognitive processes were grouped together. The Brief Developmental Assessment 
cognitive score within the youngest age band consisted of four domains and within the 
older four age bands consisted of five domains, hence generating a maximum total score 
of 16 under the age of 17 weeks, and 20 between 17 weeks and 5 years.  
 In order to address expected incremental developmental achievements with increasing 
age, for each age band the 4 items within each domain were placed in order of increasing 
difficulty. A child at the bottom of a given age band (youngest) would be likely to complete 
fewer items than a child at the top of the same age band (oldest). Therefore in addition 
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to ordering the items, the age range for each age band was also divided into quarters, and 
the expected ‘normal’ score range within each age quartile was identified (Green), as well 
as the lower scores determining Amber and Red. Thus for each domain there was a clear 
process for translating the number of items achieved into Red/Amber/Green based on 
the precise age of the child. (An example of this is given in the supplementary material, 
Figure 1).  
 
 
Internal reliability  
Internal reliability data on 138 children based on Brief Developmental Assessment version 
two are displayed in Table 2. Of note, certain poorly performing items (Cronbach alpha <0.6) 
were revised in the next iteration of the Brief Developmental Assessment.  For example, in 
age band one the motor scale was revised to include both a gross motor domain and a fine 
motor domain in version 3, with 4 items in each.  The scores for age band one were the most 
problematic, with weak reliability, but increasingly good reliability in the older age bands.  
 
Construct validity 
The 17 children in a known group (Down syndrome: n=12, other genetic syndromes: n=5) had 
significantly lower Brief Developmental Assessment scores (median: 10; IQR: 7) than their 
age-matched counterparts (median: 16; IQR: 5.50; Z=3.08; p=0.002), with an effect size of .53 
(equating to a medium effect size). There were at least two matched pairs in each of the five 
age bands, hence individual numbers in each age band were too low for valid statistical 





Inter-rater reliability data on 74 children based on Brief Developmental Assessment version 
3 were excellent (Table 3).  In terms of inter-rater concordance for children scoring as a 
‘Red’ in each age band, there was perfect agreement on both the Brief Developmental 
Assessment gross motor and Brief Developmental Assessment cognitive score scales for 
children in each of the age bands 1-4 (Kappa = 1; p<.001).  In age band 5 no child scored 
‘Red’ on the Brief Developmental Assessment gross motor and on the Brief Developmental 
Assessment cognitive score there was again perfect agreement (Kappa = 1; p<.01).  The 
numbers of children scoring as ‘Red’ on the Brief Developmental Assessment gross motor 
were 11,4,4,5 and 0 for age bands 1-5 respectively and for the Brief Developmental 
Assessment cognitive score the numbers scoring ‘Red’ were 4,7,4,8 and 2 for age bands 1-5 
respectively. 
 
Acceptability and feasibility  
 The Brief Developmental Assessment took up to ten minutes to complete and score, 
unless there was a requirement to use an interpreter. 
 It was feasible to undertake the Brief Developmental Assessment in a ward or clinic 
setting, in terms of timing, space and integration with other ward or clinic work.  
 A range of clinicians, in particular those based in community paediatric settings, were in 
favour of the traffic lights scoring system. 
 Parents responded favourably to the Brief Developmental Assessment, reporting that the 
content was relevant to their child and they found it acceptable and useful for their child 
to be assessed with it, and nurses commented that completing the Brief Developmental 
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Assessment was a good ‘ice-breaker’ for children at pre-admission clinics and that it 
helped to build rapport with the child and family. 




The motivation for this study was firstly the acknowledgement that children undergoing 
cardiac surgery [approximately 5500 per annum in the United Kingdom39], are at  significant 
risk for subsequent neuropsychological impairment2-4, secondly an awareness that the issue 
of developmental delay amongst children with CHD is of great importance to stakeholders, in 
particular patient and parent groups28, and early intervention is important for the child yet 
surveillance of neurodevelopment is not part of routine care and thirdly our realisation that 
the National Health Service is under immense resource pressure and constraint and hence 
will never foreseeably be able to support a model based on the recent recommendations for 
specialist neurodevelopmental follow up of all children with CHD23. Rather, we hope to 
develop a patient pathway that takes advantage of the structure of the National Health 
Service and existing services for children with CHD that has a better chance of success, noting 
that CHD services in the United Kingdom are centralised, and neurodevelopmental services 
are based in secondary care settings.  Therefore it is important to be able to identify children 
who need further assessment but not to overburden the system by routinely referring all 
children. To this end, the Brief Developmental Assessment has been developed. It is 
important to emphasise that the Brief Developmental Assessment does not represent a full 
neurodevelopmental assessment - rather it is an early recognition tool, which may be used to 
raise awareness of neurodevelopmental issues in CHD and trigger more timely evaluations of 
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neurodevelopment, in the most vulnerable children by appropriate practitioners.   
Furthermore, given that neurodevelopmental deficits may not emerge or be apparent from 
the outset, some deficits may “recover” spontaneously and there is also the potential for the 
level of risk to change over time related to clinical factors, the Brief Developmental 
Assessment provides a mechanism for regular screening, as recently recommended23.   
 
Despite the existence of many validated tests – both those designed for comprehensive 
evaluation and screening tests (see Supplementary Table 1) – of neuropsychological 
functioning in children, we were unable to identify an early recognition tool for use in children 
with CHD that fulfilled criteria established by a multidisciplinary team of experts. In particular, 
in order to meet the demands of a busy clinical service and a high patient volume within a 
financially constrained system, it will be necessary for such assessments to be undertaken by 
nurses or junior doctors (with appropriate training) rather than by developmental specialists.  
The use of screening and early-recognition tools by non-specialist health professionals has 
been reported across a wide range of measures and professional groups34, 40 and their use by 
non-specialists is considered to be acceptable as well as practical given the remit and 
requirements of such tools.   Assessments need to be feasible without specialist equipment 
(although more generic items such as paper and crayons would be expected to be available 
on a paediatric ward) and need to be able to be completed and scored relatively quickly. 
Assessment and surveillance are required across the range of ages from birth to adolescence 
and particularly up to the age of five years when children start school since these are the ages 
at which cardiac interventions, in some cases serial interventions, are undertaken. 
Furthermore, assessment must incorporate the key domains of neurodevelopment which are 
known to be at risk in children born with CHD who may sustain brain injuries before41 or soon 
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after birth42 or around the time of surgery2, 4 and should include direct observations and not 
rely entirely on parental report in order to minimise bias43. Finally, it is important that 
completion and scoring of a measure should provide cues for further, timely, evaluation and 
treatment (previously referred to as a useful guide to action)34. 
 
Development of the Brief Developmental Assessment incorporated a thorough and iterative 
process involving a multidisciplinary panel of experts and a review of the literature to inform 
item selection, thus ensuring acceptable face and content validity.  A similar approach has 
recently been reported in the development and validation of an early childhood development 
scale for use in low resourced settings44.  There was iterative testing with revisions informed 
by feedback and a strong steer for the Brief Developmental Assessment to be practical, 
acceptable and feasible to use in routine clinical practice, hence the inclusion of a traffic light 
system to aid interpretation of the results and guide actions. As reported, preliminary testing 
of the Brief Developmental Assessment was encouraging, with excellent inter-rater reliability 
and reasonable internal consistency for most domains. Some domains in version two had low 
alpha coefficients which may suggest that these were not measuring the same construct 
and/or may be related to the relatively small number of items in the subscales and the small 
numbers of children involved in the preliminary testing.  On the preliminary assessment of 
construct validity, the Brief Developmental Assessment distinguished those in a known group 
from those not in a known group but this may not hold true for the youngest age babies since 
developmental delay as a result of a syndrome has not manifested. A number of issues were 
identified related to understanding and clarity of certain items, and to ensure consistency of 
administration and scoring and to minimise any ambiguity a detailed training guide was 




Moving forwards, it evident that there is a need for results of the Brief Developmental 
Assessment to be linked to a referral pathway which is appropriate and acceptable to 
clinicians working in different settings. The lack of such a pathway is a clear limitation and 
needs to be addressed during the next stage of work. To that end a Delphi survey involving 
professionals from various disciplines and across sectors in the United Kingdom is currently 
underway. Furthermore, the Brief Developmental Assessment, now developed, requires full 
formal validation with an appropriately powered sample in each age group. This has now been 
completed45 and includes an evaluation of the sensitivity and specificity of the Brief 
Developmental Assessment against the gold-standard tests29. Consideration also needs to be 
given to the impact of false negatives and false positives for families as well as health 
professionals46.  It is clearly important for an early recognition tool to have a low false negative 
rate but it has also been suggested that the rate of false positives should be no more than 
30%47. Finally, prior to wider implementation of the Brief Developmental Assessment, a 
training package will need to be developed. 
 
Conclusion 
We have reported the development and initial stages of testing of an early recognition tool 
for use with children with CHD: the Brief Developmental Assessment. Our aim is to fill a gap 
in the health surveillance of children with CHD and to address a significant and increasingly 
common event – namely impaired neurodevelopmental functioning – by facilitating early, 
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Table 1: Consensus based criteria for neurodevelopmental assessment tool 
 
Applicable to the patient population in 
need (children with heart disease), in 
terms of age range and relevant 
domains of development. 
 Test age ranges of 0-4.9 years. 
 Covers the important domains of gross motor, 
fine motor, daily living skills, communication, 
socialisation and general understanding. 
Measure could be feasibly deployed in a 
busy cardiac ward or clinic. 
 Staff able to administer the test (with training) 
must be non-specialists in neurodevelopment 
such as competent nurses. 
 Testing process does not require any specialist 
equipment such as particular puzzles, pictures 
or other bricks of a specific size; more generic 
items such as paper and crayons acceptable. 
 Quick to administer (less than 10 minutes). 
Results convey a useful guide to action.  Quick to score and not requiring specialist 
software. 
Measure contains accurate responses 
with minimised reporting bias. 
 Test includes elements of direct observation 




















Table 2: Results of preliminary internal reliability testing based on Cronbach alpha values 
 Age Band 
One 







35-60 weeks  
Age Band 
Four 
15 months – 
2.9 years  
Age Band Five 
3.0-4.9 years  
Number included 25 31 23 37 22 
All individual 
items* 




0.39 0.57 0.68 0.87 0.73 
Within each 
domain: 
     
Gross motor  0.19  0.39  0.72 0.76 0.69 
Fine motor N/A N/A 0.17  0.78 0.35 
Daily living skills 0.61 0.70 0.48 0.80 0.29  
Communication 0.06 0.40 0.54 0.71 0.14  
Socialisation 0.16  0.67 0.28  0.75 0.54  
 
*’All individual items’ refers to each individual item on the whole scale, irrespective of which 
domain. 
**Domains other than the gross motor domain were grouped together (referred to as BDA 
Cognitive); the Cronbach alpha value represents the internal reliability of the domain total 





















Table 3: Results of preliminary inter-rater reliability testing 
 















Age Band One 
0-16 weeks 
23  1 < 0.001 23 0.98 (0.96, 0.99) < 0.001 
Age Band Two 
17-34 weeks 




15  0.91 (0.63, 1) < 0.001 14 0.94 (0.82, 0.98) < 0.001 
Age Band Four 
15 months-2.9 
years 
17 1 < 0.001 16 1.00 (0.99, 1.00) < 0.001 
Age Band Five 
3-4.9 years 
8 1 < 0.001 8 1.00  . 
 
BDA Cognitive: total for all subscales other than gross motor subscale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
